Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities
- PMID: 34856197
- DOI: 10.1016/S2468-1253(21)00432-5
Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities
Conflict of interest statement
CM has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pfizer, and Roche; speaker's fees from AbbVie, Amgen, AVIR Pharma, Alimentiv, Ferring, Janssen, Takeda, and Pfizer; and research support from Pfizer. MYC has received consulting fees from AstraZeneca, MitogenDx, and Janssen.
Comment on
-
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161-170. doi: 10.1016/S2468-1253(21)00377-0. Epub 2021 Nov 29. Lancet Gastroenterol Hepatol. 2022. PMID: 34856198
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical